Search Results

Thor Medical Advances AlphaOne Commercial Production in H1, Completes First Customer Deliveries of Lead-212 Isotope

Thor Medical ASA, a supplier of high-purity isotopes to the radiopharmaceutical industry, announced its H1 2026 results on August 28. The company stated that its AlphaOne facility has completed mechanical construction on time and on budget and has entered commercial production, marking the start of a new phase focused on scaling output, increasing customer deliveries, and growing revenue. Thor Medical CEO Jasper Kurth said that with the completion of the first customer product deliveries from AlphaOne, the company has established a solid commercial foundation in a rapidly growing market, and the next step is to advance the execution plan around capacity expansion, customer deliveries, and revenue growth to support the development of next-generation precision cancer therapies...

2026-08-28

South Korea's Medical Radiation Examinations Exceed 430 Million Annually, with CT Scans Accounting for 67.1% of Radiation Dose

According to the "2025 National Medical Radiation Assessment Yearbook" released by the Korea Disease Control and Prevention Agency on August 28, South Koreans underwent a total of 431.59 million medical radiation examinations last year, averaging 8.4 examinations per person. Over the past five years, the number of medical radiation examinations in South Korea has continued to rise, with last year's figure increasing by 4.6% year-on-year and 29.6% compared to 2021. The report shows that the collective radiation dose from medical radiation examinations in South Korea increased from 136,804.73 person-sieverts in 2021 to 167,659.18 person-sieverts last year, an increase of 22.6%. On a per capita basis, the radiation dose rose from 2.64 millisieverts to 3.24 millisieverts. The Korea Disease Control and Prevention Agency stated that with advances in medical technology, an aging population, and growing demand for health checkups, the use of medical radiation examinations in public healthcare services continues to expand.

2026-08-28

China Unicom Yantai Branch and CNNC Shandong Build 5G Dedicated Network for Nuclear Power

Recently, the 5G dedicated network project jointly built by China Unicom Shandong Yantai Branch and CNNC Shandong was officially deployed and put into operation. Targeting the requirements of nuclear power scenarios for communication network security, reliability, and low latency, the project introduces technologies such as 5G dedicated networks, edge computing, artificial intelligence, and big data to promote the implementation of digital capabilities in nuclear power park construction and production support scenarios. CNNC Shandong, affiliated with China National Nuclear Corporation, undertakes tasks related to nuclear power unit power generation and grid connection. During project construction, China Unicom Shandong Yantai Branch, in collaboration with Huawei, adopted end-to-end domestically produced equipment, achieving independent controllability in both hardware and software, filling the gap in domestic 5G dedicated network construction in the nuclear power sector...

2026-08-28

Multiple African countries push nuclear power projects from planning to financing and construction

According to the nuclear energy special report in the recently released "Nuclear Industry Insights, Fourth Quarter 2026," more than a dozen African countries are attempting to advance nuclear power from policy concepts to financeable, constructible project stages. The report notes that rising demand for reliable, low-carbon baseload power is an important backdrop for nuclear energy's return to Africa's energy strategy discussions. Currently, two of Africa's more advanced nuclear projects have reached new milestones. The reactor pressure vessel for Unit 2 of Egypt's El Dabaa Nuclear Power Plant was installed on July 9, 2026. Previously, Unit 1 completed a similar installation in November 2025. El Dabaa is Egypt's first nuclear power plant, planned with 4 units and a total installed capacity of 4...

2026-08-28

Russia's Kursk Nuclear Power Plant Releases Annual Environmental Report

Russia's Kursk Nuclear Power Plant recently presented its annual environmental report to local residents in the city of Kurchatov. This year's presentation adopted a cycling event format for the first time, with participants including local residents, city Duma deputies, and relevant personnel, held in the area of Warm Coast Park. The Kursk Nuclear Power Plant is part of Rosenergoatom, the power generation division operator of Russia's state nuclear corporation Rosatom. The plant stated that the event route was specially designed to allow participants to learn about environmental protection data during the ride and directly observe the environmental conditions in the area surrounding the plant. Kursk...

2026-08-28

Russian Thorium-Based Radiopharmaceuticals Expected Within 1-2 Years

On August 27, Igor Korobko, Professor of the Russian Academy of Sciences and Director of the Department of Medical and Scientific Development in Healthcare of the Russian Ministry of Health, stated at the Technoprom Forum held in Novosibirsk that thorium-based drugs for precision radionuclide therapy of tumors are expected to become available in Russia within the next 1 to 2 years. Korobko noted that tumor treatment still requires support from more available isotopes. For example, when patients develop resistance to actinium-related therapies, clinical practice necessitates the use of different isotopes for treatment. He stated that Russia is advancing the development of related therapies domestically and expects to have thorium-based drugs within the next year or two. Currently, actinium-225 is considered one of the more promising radionuclides...

2026-08-28

Russia Advances Radiopharmaceutical Development, Plans to Expand into Diagnostics and Treatment of Heart Disease and Other Conditions

Rosatom is developing radiopharmaceuticals for the diagnosis and treatment of neurodegenerative diseases, heart disease, and rheumatic conditions, further expanding the application of radionuclide technology in medicine. During the 13th International Technology Development Forum Technoprom-2026 held in Novosibirsk, Sergei Surov, Director of the Department of Radionuclide Products and Nuclear Medicine at Rosatom's Science Division, stated that the company is advancing the development of these drugs. Radiopharmaceuticals typically contain radioactive isotopes, i.e., radionuclides, and are currently used in medicine primarily for the diagnosis and treatment of various cancers. Surov noted that the new development directions mean...

2026-08-28

Russia and Egypt Plan to Cooperate on Construction of Nuclear Medicine Center and Radiopharmaceutical Plant

Alexey Likhachev, CEO of Rosatom, recently stated that Russia and Egypt are expanding cooperation in non-energy nuclear technologies, with one of Egypt's key priorities being the construction of a high-performance nuclear medicine center based on a research reactor. According to reports, the project will adopt a comprehensive approach, including a radiopharmaceutical production plant, isotope production facilities, and modern diagnostic systems based on PET and SPECT technologies. Some diagnostic systems will use Russian equipment. Once completed, the project is expected to conduct up to 30,000 diagnostic examinations annually and provide treatment services for 400 patients. Construction of the medical facility is expected to begin as early as 2027...

2026-08-28

Bristol Myers Squibb to Invest $173 Million in New Radiopharmaceutical Plant in Indiana, USA

Bristol Myers Squibb's RayzeBio will build a new radiopharmaceutical production facility in Whitestown, Indiana, USA, with an investment of $173 million. The project will be located at the Anson Industrial Park in Boone County, with construction planned to begin this year, complementing RayzeBio's existing operational radiopharmaceutical plant in Indianapolis. According to information released by the state of Indiana, the new facility will cover approximately 225,000 square feet. Bristol Myers Squibb expects the two production sites to add 100 new positions by the end of 2029, with annual salaries for new positions expected to exceed $130,000. Bristol Myers Squibb acquired San Diego-based RayzeBio in 2023 for $4.1 billion...

2026-08-28

Egyptian Minister of Electricity Inspects Small Modular Reactor Technology in Russia

On August 27, 2026, Egyptian Minister of Electricity and Renewable Energy Mahmoud Esmat visited a small nuclear reactor manufacturing and assembly plant operated by Rosatom during an official visit to Russia. The inspection focused on the latest advancements in small modular reactor-related technologies, industrial application status, and potential cooperation opportunities between the two sides. The Egyptian side stated that such visits align with the country's direction of diversifying energy sources and enhancing the security and sustainability of electricity supply. During the visit, Esmat was briefed on the manufacturing and assembly processes of small reactor components, as well as related safety systems...

2026-08-28

Fukui Prefecture in Japan Aims to Promote Local Utilization of Nuclear Power

On the 27th, Fukui Prefecture in Japan held a co-creation meeting to exchange views on development measures for areas hosting nuclear power plants. The meeting confirmed a new policy aimed at promoting the local use of electricity generated by nuclear plants to drive related industrial development, including attracting large-scale data centers and other high-power-consuming businesses. Fukui Prefecture has held co-creation meetings for the past five consecutive years, with participants including the Fukui Prefectural Government, local governments in areas within the prefecture hosting nuclear plants, Japan's central government, and representatives of electric power companies. The meeting focused on how to combine the stable power supply and carbon-dioxide-free operation of nuclear plants with regional industrial revitalization...

2026-08-28

Cambridge AtomWorks Opens New Laboratory at Granta Park to Develop ODIN Microreactor

Cambridge AtomWorks announced on August 27 that its new light industrial facility and laboratory at Granta Park in Cambridge, UK, has officially entered service. The site, leased from TWI (The Welding Institute), will be used to advance research and development work related to the ODIN microreactor. According to the company, the new laboratory has already begun conducting experiments closely linked to ODIN microreactor development, including studies on coolant properties and behavior. The research team is using an STA-MS system to characterize material properties related to fuel performance, which enables simultaneous thermogravimetric analysis, heat flow analysis, and mass spectrometry. The new facility will also be used for reactor flow...

2026-08-28

Bruce Power Aims to Generate Over CAD 13.3 Billion in Economic Impact in Canada Over Next 18 Months

Bruce Power recently stated that over the next 18 months, the company expects to generate more than CAD 13.3 billion in economic impact across Canada, with related investments primarily stemming from its nuclear plant operations and life extension programs, supporting businesses and jobs in Ontario and other regions of Canada. Bruce Power stated that since launching the "Canada First" program in 2025, the company has invested over CAD 6.6 billion in Canada between January 2025 and June 2026, and plans to invest an additional CAD 7.7 billion by the end of 2027. The company noted that its spending within Canada accounts for more than 95% of total expenditures. As a nuclear operator located in Bruce County, Ontario...

2026-08-28

Qinshan Nuclear Power Membrane Deoxygenation Retrofit Project Put into Operation

Recently, the membrane deoxygenation retrofit project at Qinshan Nuclear Power completed commissioning and was put into operation. The project applies membrane deoxygenation technology to the auxiliary feedwater system (ASG) and reactor boron and water makeup system (REA) of Units 1 and 2 at Qinshan Nuclear Power Plant Phase II, optimizing and upgrading the original deoxygenation process. Units 1 and 2 of Qinshan Phase II originally adopted thermal deoxygenation. During long-term operation, this method presented issues such as insufficient redundancy in single-train equipment operation, high temperature and humidity on site, and potential exceedance of auxiliary feedwater tank temperature limits during summer peak temperature periods. To enhance system operational reliability, Qinshan Nuclear Power initiated relevant technical retrofits, introducing membrane separation packaged units to form a parallel standby configuration with the original thermal deoxygenation system, allowing flexible switching...

2026-08-28

Lufeng Nuclear Power Unit 1 Nuclear Island Installation and High-Quality Cold Test Sand Table Exercise Successfully Concluded

From August 18 to August 21, 2026, the China Nuclear Energy Association (hereinafter referred to as the Association) organized relevant experts to successfully carry out the sand table exercise for the nuclear island installation and high-quality cold test of Lufeng Nuclear Power Unit 1. The sand table exercise was led by Hu Guofeng, former Director of Shanghai Nuclear Engineering Research and Design Institute Co., Ltd. and Deputy Director of the Science, Technology and Development Expert Committee, with Li Jingxi, former Director of the South China Nuclear and Radiation Safety Supervision Station of the Ministry of Ecology and Environment, Li Qibin, former Chairman of China Nuclear Industry 23 Construction Co., Ltd., Zeng Hao, former Chairman of CNNC Maintenance Co., Ltd., and Wang Mingliang, former Deputy General Manager of China Nuclear Industry Fifth Construction Co., Ltd., serving as advisors. A total of 24 external experts participated...

2026-08-28